BioMark Diagnostics' market value is the price at which a share of BioMark Diagnostics trades on a public exchange. It measures the collective expectations of BioMark Diagnostics investors about its performance. BioMark Diagnostics is trading at 0.36 as of the 23rd of January 2026. This is a 12.50 percent increase since the beginning of the trading day. The stock's lowest day price was 0.35. With this module, you can estimate the performance of a buy and hold strategy of BioMark Diagnostics and determine expected loss or profit from investing in BioMark Diagnostics over a given investment horizon. Check out BioMark Diagnostics Correlation, BioMark Diagnostics Volatility and BioMark Diagnostics Alpha and Beta module to complement your research on BioMark Diagnostics.
Please note, there is a significant difference between BioMark Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioMark Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioMark Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioMark Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioMark Diagnostics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioMark Diagnostics.
0.00
10/25/2025
No Change 0.00
0.0
In 2 months and 31 days
01/23/2026
0.00
If you would invest 0.00 in BioMark Diagnostics on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding BioMark Diagnostics or generate 0.0% return on investment in BioMark Diagnostics over 90 days. BioMark Diagnostics is related to or competes with Izotropic, Marpai, DIAGNOS, Celyad Oncology, Rubicon Organics, and Starpharma Holdings. BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and asse... More
BioMark Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioMark Diagnostics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioMark Diagnostics upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioMark Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioMark Diagnostics' standard deviation. In reality, there are many statistical measures that can use BioMark Diagnostics historical prices to predict the future BioMark Diagnostics' volatility.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioMark Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioMark Diagnostics appears to be out of control, given 3 months investment horizon. BioMark Diagnostics secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. By analyzing BioMark Diagnostics' technical indicators, you can evaluate if the expected return of 0.82% is justified by implied risk. Please makes use of BioMark Diagnostics' Downside Deviation of 6.87, risk adjusted performance of 0.1004, and Mean Deviation of 2.58 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BioMark Diagnostics holds a performance score of 9. The firm shows a Beta (market volatility) of 1.35, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioMark Diagnostics will likely underperform. Please check BioMark Diagnostics' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether BioMark Diagnostics' price patterns will revert.
Auto-correlation
-0.31
Poor reverse predictability
BioMark Diagnostics has poor reverse predictability. Overlapping area represents the amount of predictability between BioMark Diagnostics time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioMark Diagnostics price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current BioMark Diagnostics price fluctuation can be explain by its past prices.
Other Information on Investing in BioMark OTC Stock
BioMark Diagnostics financial ratios help investors to determine whether BioMark OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.